135 related articles for article (PubMed ID: 31605802)
1. Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients.
Savio AJ; Kamdar S; Jeyapala R; Olkhov-Mitsel E; Cuizon C; Finelli A; Zlotta AR; Toi A; Fleshner NE; van der Kwast T; Bapat B
J Mol Diagn; 2020 Jan; 22(1):30-39. PubMed ID: 31605802
[TBL] [Abstract][Full Text] [Related]
2. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
3. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
6. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
7. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
8. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
[TBL] [Abstract][Full Text] [Related]
10. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
11. Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy.
Murota-Kawano A; Nakano M; Hongo S; Shoji S; Nagata Y; Uchida T
BJU Int; 2010 Jun; 105(12):1642-5. PubMed ID: 19922544
[TBL] [Abstract][Full Text] [Related]
12. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
13. Prostate Specific Antigen Nadir After Radical Cystoprostatectomy in Patients With Benign Prostatic Tissue: A Benchmark To Define Biochemical Recurrence after Radical Prostatectomy.
Hosseini SY; Alemi M; Amini E; Riazi N
Urol J; 2019 Dec; 16(6):563-566. PubMed ID: 31004342
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
15. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
[TBL] [Abstract][Full Text] [Related]
16. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
[TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
[TBL] [Abstract][Full Text] [Related]
19. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]